8-(Dimethylamino)-7-methyl-10-(2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4-dione | 51093-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 8-(Dimethylamino)-7-methyl-10-(2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4-dione
• CAS: 51093-55-1
• 化学式: C₁₈H₂₃N₅O₆
• 分子量: 405.4
• InChiKey: IGQLDUYTWDABFK-UHFFFAOYSA-N

物化性质

• 熔点：
  276-278°C
• 密度：
  1.59±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  158
• 氢给体数：
  5
• 氢受体数：
  8

制备方法与用途

生物活性

Roseoflavin 是一种天然色素，最初从 Streptomyces davawensis 中分离出来。它是核黄素和黄素单核苷酸（FMN）的抗代谢类似物，并具有抗菌作用。

体外研究

Roseoflavin 能够直接与 FMN 核糖开关 aptamer 结合（解离常数 ( K_d ) 约为 100 nM），从而下调枯草芽孢杆菌（B. subtilis）中 FMN 核糖开关 - lacZ 报告基因 的表达。

文献信息

• COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS
  申请人：Avedro Inc.

  公开号：EP3890741A1

  公开（公告）日：2021-10-13
• [EN] COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITEMENTS OCULAIRES
  申请人：AVEDRO INC

  公开号：WO2020117974A1

  公开（公告）日：2020-06-11

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that that generates cross-linking in the cornea in response to exposure to an electromagnetic irradiation. This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which in which abnormal shaping of the cornea (e.g., thinning of the cornea, e.g., bilateral thinning of the cornea, e.g., bilateral thinning of the central, paracentral, or peripheral cornea; or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g., post-operative ectasia, e.g., post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism, and presbyopia.